Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
37.56%
median of 685 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Enliven Therapeutics, Inc.
Market Cap
$3.09B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.09B
Gross Margin
0.00%
TTM Avg
25.88%
3Y Avg
57.90%
5Y Avg
-575.35%
Market Cap
$3.09B
Gross Margin
91.14%
TTM Avg
90.25%
3Y Avg
87.92%
5Y Avg
58.61%
Market Cap
$3.13B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
66.67%
Market Cap
$2.89B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.82B
Gross Margin
58.69%
TTM Avg
59.64%
3Y Avg
63.22%
5Y Avg
64.62%
Market Cap
$3.41B
Gross Margin
-360.00%
TTM Avg
-180.00%
3Y Avg
-491.57%
5Y Avg
-334.18%
Market Cap
$3.41B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.09B | 0.00% | 0.00% | 0.00% | 0.00% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | 0.00% | 25.88% | 57.90% | -575.35% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.09B | 91.14% | 90.25% | 87.92% | 58.61% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.13B | 0.00% | 0.00% | 50.00% | 66.67% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.89B | 0.00% | 0.00% | 0.00% | 0.00% |
| TransMedics Group, Inc. (TMDX)vs › | $2.82B | 58.69% | 59.64% | 63.22% | 64.62% |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 76.16% | 74.55% | 74.69% | 74.35% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.41B | -360.00% | -180.00% | -491.57% | -334.18% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.41B | 0.00% | 0.00% | 0.00% | 0.00% |
| CareDx, Inc (CDNA)vs › | $3.43B | 70.58% | 67.35% | 65.86% | 66.29% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
